Skip to content
OpenCapital
Get started

Harrow HROW Compounding — Revenue

Other segment segments

Branded
$30.7M+10.5%

Similar metrics at other companies

Ocular Therapeutix logo
OCULProduct — Revenue
$10.79M+1.4%
LQD
LQDAProduct — Revenue
$129.88M—
Nuvation Bio logo
NUVBProduct Revenue — Revenue
$18.5M+2,213%
PTC Therapeutics logo
PTCTProduct — Revenue
$225.57M+47.0%
Kiniksa Pharmaceuticals International, plc logo
KNSAProduct — Revenue
$214.27M+55.5%
Nuvation Bio logo
NUVBProduct — Revenue
$18.51M—

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.81B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's compounding — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's compounding — revenue?
Harrow (HROW) reported compounding — revenue of $13.5M in Q1 2026.
How has Harrow's compounding — revenue changed year-over-year?
Harrow's compounding — revenue decreased by 32.7% year-over-year, from $20.05M to $13.5M.
What does compounding — revenue mean?
This metric represents the total net revenue generated from the sale of compounded ophthalmic pharmaceutical products to customers, excluding any collected sales taxes. It serves as a primary indicator of market demand and commercial success within the company's specialized compounding business segment. Tracking this figure helps investors evaluate the scale and growth trajectory of the compounding product portfolio.